ReviewDrugs & aging2016
Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application.
Review in Drugs & aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- A meta-analysis of the local application of vancomycin powder to prevent surgical site infection after spinal surgeries.The Journal of international medical research · 2020Pooled it
- Population Pharmacokinetics and Clinical Application of Vancomycin in Critically Ill Adults: A NONMEM-Based Review.Drug design, development and therapy · 2026Review
- Vancomycin Rx stewardship training for pharmacist.Journal of pharmaceutical policy and practice · 2025Article
- Decreased Kidney Function Explains Higher Vancomycin Exposure in Older Adults.Drugs & aging · 2024Observational
- Age-Related Differences in Vancomycin-Associated Nephrotoxicity and Efficacy in Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Reconsideration of the current models of estimated kidney function-based drug dose adjustment in older adults: The role of biological age.Clinical and translational science · 2023Review
- Review
- Research progress and future prospects of antimicrobial modified polyetheretherketone (PEEK) for the treatment of bone infections.Frontiers in bioengineering and biotechnology · 2023Review
- Clinical validation of the two-point method for predicting vancomycin AUC based on peak and trough plasma concentrations.International journal of clinical pharmacy · 2022Article
- Is Vancomycin More Effective than Taurolidine? Comparative Analysis of Their Preventive Effect against Spinal Infection in 1000 Patients with Spinal Fusion.Antibiotics (Basel, Switzerland) · 2022Article
- Infective Endocarditis in the Elderly: Challenges and Strategies.Journal of cardiovascular development and disease · 2022Review
- Blood Culture Utilization in the Hospital Setting: a Call for Diagnostic Stewardship.Journal of clinical microbiology · 2022Review
- Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data.Frontiers in pharmacology · 2022Article
- Causes of vancomycin dosing error; problem detection and practical solutions; a retrospective, single-center, cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- Drug-Induced Kidney Injury in the Elderly.Drugs & aging · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The elderly population can be divided into three distinct age groups: 65-74 years (young-old), 75-84 years (middle-old), and 85+ years (old-old). Despite evidence of a shift in leading causes for mortality in the elderly from infectious diseases to chronic conditions, infections are still a serious cause of death in this population. These patients are at increased risk due to weakened immune systems, an increased prevalence of underlying comorbidities, and decreased physiologic reserves to fight infection. Additionally, elderly patients, especially adults in institutional settings, are at an increased risk of colonization and subsequent infection with methicillin-resistant Staphylococcus aureus at a rate that is five times higher than in younger individuals, causing an increase in empiric and definitive vancomycin use. Elderly patients have unique characteristics that make dosing vancomycin a challenge for clinicians, such as increased volume of distribution and decreased renal function. Using the best available evidence, it is recommended to initiate lower empiric maintenance doses and monitor vancomycin serum concentrations earlier than steady state to accurately calculate drug elimination and make appropriate dose adjustments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.